November 1, 2023 11:12 AM EDT
News Briefing

Tonix's de­pres­sion fail; Lil­ly ex­er­cis­es op­tion in Sit­ryx deal; Mil­ner stops fight against Ab­cam ac­qui­si­tion

Ayisha Sharma

News Reporter

Jaimy Lee

Deputy Editor

Tonix drops de­pres­sion drug af­ter PhII fail­ure: Tonix Phar­ma­ceu­ti­cals is dis­con­tin­u­ing its ma­jor de­pres­sive dis­or­der pro­gram, TNX …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times